Loading…
Cadrenal Therapeutics, Inc. is projected to decline to $2.44 by 2027, a -16% move from its current price of $2.89. CVKD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.74 | $2.89 | $3.05 | +0.02% |
| Jul 13 | $2.69 | $2.89 | $3.11 | +0.04% |
| Jul 14 | $2.64 | $2.89 | $3.17 | +0.06% |
| Jul 15 | $2.61 | $2.89 | $3.21 | +0.08% |
| Jul 16 | $2.57 | $2.89 | $3.25 | +0.10% |
| Jul 17 | $2.55 | $2.89 | $3.29 | +0.12% |
| Jul 18 | $2.52 | $2.89 | $3.32 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.52 | $2.89 | $3.32 | +0.13% |
| Week 2 | $2.38 | $2.90 | $3.52 | +0.27% |
| Week 3 | $2.28 | $2.90 | $3.69 | +0.40% |
| Week 4 | $2.20 | $2.91 | $3.83 | +0.54% |
| Week 5 | $2.14 | $2.91 | $3.96 | +0.67% |
| Week 6 | $2.08 | $2.91 | $4.09 | +0.81% |
| Week 7 | $2.02 | $2.92 | $4.21 | +0.94% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation.
CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial.
It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc. (CVKD) trades in the Healthcare sector with a current price of $2.89. Its market capitalization is $8.9M and its rank is 5118.
The asset’s price outlook is mixed in the near term, transitioning through a neutral stance in 2026 to bearish in the near term years and then turning bullish in the longer term, with notable projected gains by 2030, 2040, and 2050. In 2026 the avg is $2.89 with a min of $2.86 and a max of $3.48 (ROI 0, sentiment NEUTRAL). By 2030 the avg reaches $3.48 (ROI 20.4) with a bullish sentiment, and by 2040 the avg is $4.14 (ROI 43.4) and by 2050 the avg is $9.03 (ROI 212.6), both with bullish sentiment.
A major floor 50.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.0% away) — a key level to hold.
The nearest ceiling, 73.0% above — a clean break opens room to run.
A major ceiling 187.2% above — clearing it would confirm fresh momentum.
Key CVKD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CVKD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.10 | Sell | $3.06 | Sell |
| MA 10 | $3.17 | Sell | $3.15 | Sell |
| MA 20 | $3.22 | Sell | $3.37 | Sell |
| MA 50 | $4.41 | Sell | $4.13 | Sell |
| MA 100 | $5.33 | Sell | $5.24 | Sell |
| MA 200 | $7.75 | Sell | $7.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.43 | Neutral |
| Stoch RSI (14) | 43.56 | Neutral |
| CCI (20) | -97.15 | Neutral |
| Williams %R (14) | -95.95 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | -5.56 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 4.05 | Buy |
| TRIX (15) | -1.49 | Sell |
| Awesome (5,34) | -0.70 | Sell |
| Ultimate (7,14,28) | 34.11 | Neutral |
| Momentum (10) | 0.03 | Buy |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 2.96 | Sell |
| ADX (14) | 26.62 | Sell |
| ATR (14) | 0.19 | Info |
The 30-day technical picture shows a range from $2.05 to $4.08, with a current neutral tilt and RSI(14) at 40.
The stock is trading below both the 50-day simple moving average ($4.41) and the 200-day simple moving average ($7.75). Support is identified at $2.86 and resistance at $5.00.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.86 | $2.89 | $3.48 | 0% | Neutral | |
| $1.78 | $2.44 | $3.62 | -16% | Bearish | |
| $1.51 | $2.20 | $3.47 | -24% | Bearish | |
| $2.00 | $3.07 | $5.08 | +6% | Neutral | |
| $2.17 | $3.48 | $5.99 | +20% | Bullish | |
| $1.96 | $3.28 | $5.84 | +13% | Neutral | |
| $1.96 | $3.42 | $6.29 | +18% | Neutral | |
| $1.72 | $3.13 | $5.90 | +8% | Neutral | |
| $1.52 | $2.86 | $5.53 | -1% | Neutral | |
| $1.57 | $3.08 | $6.10 | +7% | Neutral | |
| $1.86 | $4.14 | $9.01 | +43% | Bullish | |
| $4.07 | $9.03 | $20.78 | +213% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.86 | $2.89 | $3.47 | +0.00% |
| August 2026 | $2.31 | $2.80 | $3.52 | -3.23% |
| September 2026 | $2.40 | $2.94 | $3.78 | +5.16% |
| October 2026 | $2.36 | $2.93 | $3.83 | -0.34% |
| November 2026 | $2.14 | $2.69 | $3.57 | -8.22% |
| December 2026 | $2.05 | $2.59 | $3.48 | -3.68% |
Click any year to see its month-by-month CVKD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CVKD to range from $2.86 to $3.48 through 2026. The $2.89 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The CVKD price prediction for 2027 points to an average of $2.44 (low $1.78, high $3.62) — a potential decline of -16% on today's $2.89. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2028, CVKD is projected to trade between $1.51 and $3.47, averaging $2.20 — a potential decline of -24% from today's $2.89. That is -10% versus the projected 2027 average. Expect choppier, lower action through this leg of the cycle.
Cadrenal Therapeutics, Inc.'s 2029 outlook centres on $3.07, within a $2.00 to $5.08 range. That is up +40% on the projected 2028 average. That marks a +6% change versus current levels. Price action looks broadly range-bound.
By 2030, CVKD could reach as high as $5.99, with a base case around $3.48 and support toward $2.17 — roughly +20% from $2.89. Buyers look set to stay in control over this stretch.
Expect CVKD to range from $1.96 to $5.84 through 2031. The $3.28 average target implies a +13% move from current prices. That is -6% versus the projected 2030 average. Price action looks broadly range-bound.
The CVKD price prediction for 2032 points to an average of $3.42 (low $1.96, high $6.29) — a potential gain of +18% on today's $2.89. A consolidation phase looks the most probable path here.
In 2033, CVKD is projected to trade between $1.72 and $5.90, averaging $3.13 — a potential gain of +8% from today's $2.89. That is -9% versus the projected 2032 average. Price action looks broadly range-bound.
Cadrenal Therapeutics, Inc.'s 2034 outlook centres on $2.86, within a $1.52 to $5.53 range. That is -9% versus the projected 2033 average. That marks a -1% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, CVKD could reach as high as $6.10, with a base case around $3.08 and support toward $1.57 — roughly +7% from $2.89. Price action looks broadly range-bound.
Expect CVKD to range from $1.86 to $9.01 through 2040. The $4.14 average target implies a +43% move from current prices. That is up +35% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The CVKD price prediction for 2050 points to an average of $9.03 (low $4.07, high $20.78) — a potential gain of +213% on today's $2.89. Momentum favours further upside here.
Investing $1,000 in CVKD today (≈ 346.020761 CVKD) could be worth
$3,125.99
+$2,125.99 (+213%) by 2050 · US Dollar
Based on the average projected CVKD price of $9.03 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CVKDwould be worth at today's price.
$1,000 invested in CVKD on Jul 10, 2025 (≈ 76.923077 CVKD) would be worth
$222.31
-$777.69 (-77.8%) today · 0.22× · US Dollar
Based on a CVKD entry price of $13 vs. today's $2.89.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.6 | $802.78 | -19.7% |
| 1 month ago | $4.14 | $698.07 | -30.2% |
| 3 months ago | $4.76 | $607.14 | -39.3% |
| 6 months ago | $8.53 | $338.8 | -66.1% |
| 1 year ago | $13 | $222.31 | -77.8% |
| All time (3.5y) ago | $61.8 | $46.76 | -95.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CVKD forecast.
Our base-case forecast reaches $5.80 around 2050.
Implied market cap at $5.80: $17.85M
2026 forecast: min $2.86, avg $2.89, max $3.48, ROI 0, sentiment NEUTRAL.
2027 forecast: min $1.78, avg $2.44, max $3.62, ROI -15.6, sentiment BEARISH.
2028 forecast: min $1.51, avg $2.20, max $3.47, ROI -24, sentiment BEARISH.
2029 forecast: min $2.00, avg $3.07, max $5.08, ROI 6.1, sentiment NEUTRAL.
2030 forecast: min $2.17, avg $3.48, max $5.99, ROI 20.4, sentiment BULLISH.
2031 forecast: min $1.96, avg $3.28, max $5.84, ROI 13.4, sentiment NEUTRAL.
2032 forecast: min $1.96, avg $3.42, max $6.29, ROI 18.4, sentiment NEUTRAL.
2033 forecast: min $1.72, avg $3.13, max $5.90, ROI 8.2, sentiment NEUTRAL.
2034 forecast: min $1.52, avg $2.86, max $5.53, ROI -1.1, sentiment NEUTRAL.
2035 forecast: min $1.57, avg $3.08, max $6.10, ROI 6.6, sentiment NEUTRAL.
2040 forecast: min $1.86, avg $4.14, max $9.01, ROI 43.4, sentiment BULLISH.
2050 forecast: min $4.07, avg $9.03, max $20.78, ROI 212.6, sentiment BULLISH.
Tap a question to reveal the answer.
The forecast shows avg $3.48 with ROI 20.4 and sentiment BULLISH (min $2.17, max $5.99).
Forecasts show a mix of neutral, bearish, and bullish years: NEUTRAL in 2026 (avg $2.89, ROI 0), BEARISH in 2027-2028, then BULLISH in 2030, 2040, and 2050. These are estimates and not guarantees.
The max forecast in 2050 is $20.78, indicating a path to above $10 under the projection, but this remains an estimate with no guarantee.
Current price is $2.89 and market cap is $8.9M.
2040 forecast: avg $4.14, min $1.86, max $9.01, ROI 43.4, sentiment BULLISH.
Cadrenal Therapeutics, Inc. Community Discussion
0Share your Cadrenal Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.